MCE 品牌
代理商厂商性质
杭州市所在地
粒细胞趋化蛋白2(GCP2)检测试剂盒
¥1890CD23分子(CD23)检测试剂盒
¥2016B-淋巴细胞趋化因子(BLC)检测试剂盒
¥1966趋化因子配体27(CCL27)检测试剂盒
¥1966内皮糖蛋白(ENG)检测试剂盒
¥2092激肽-释放酶10(KLK10)检测试剂盒
¥1932巨噬细胞来源趋化因子(MDC)检测试剂盒
¥2092血红蛋白(HB)检测试剂盒
¥1672免疫球蛋白G(IgG)检测试剂盒
¥1806内皮糖蛋白(ENG)检测试剂盒
¥1924PARC检测试剂盒(酶联免疫吸附试验法)
¥2092FK506结合蛋白样蛋白(FKBPL)多克隆抗体
¥1621Trastuzumab 是一种人源化 IgG1 单克隆抗体,其以高亲和力与 HER2 选择性结合。Trastuzumab 可用于 HER2 阳性转移性乳腺癌和 HER2 阳性胃癌 的研究。
生物活性
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
IC50 & Target[1]
HER2
体外研究(In Vitro)
Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets[1]. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity[2]. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1[3].
体内研究(In Vivo)
Trastuzumab treatment of mouse xenograft models results in marked suppression of tumor growth. When given in combination with standard cytotoxic chemotherapeutic agents, Trastuzumab treatment generally results in statistically superior antitumor efficacy compared with either agent given alone[1]. Trastuzumab causes a significant growth inhibition of the outgrowth of macroscopic JIMT-1 xenograft tumors in both nude and SCID mice[3].
Clinical Trial
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT04158258 | Hoffmann-La Roche|Latin American Cooperative Oncology Group | February 21, 2020 | ||
NCT02774681 | Northwestern University|Pfizer|National Cancer Institute (NCI) | August 31, 2016 | Phase 2 | |
NCT03493854 | Hoffmann-La Roche | June 14, 2018 | Phase 3 |
分子量:145531.50
Formula:C6470H10012N1726O2013S42
CAS 号:180288-69-1
中文名称:曲妥珠-单抗;曲妥-单抗;群司珠-单抗
储存方式;Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
|
注:产品仅用于科研